Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

NCT02981069 · Completed

Last updated 2026-05-28

This clinical trial tested whether the medication exenatide, taken for 16 weeks, affects insulin sensitivity and beta cell function in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 90 people

Who can join Ages 18–70 · all sexes

Timeline Started 2017-12 · est. completion 2023-03

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT02981069 ↗

Description as written by the study sponsor.

In this study, the researchers hope to learn about SGLT2 inhibition on EGP (endogenous glucose production) and plasma glucose concentration in diabetic subjects. Researchers will examine diabetes and the role of increased plasma glucagon, decline in plasma insulin, and fall in plasma glucose concentration.

Treatments tested

Dapagliflozin also known as Farxiga Drug

10mg
Exenatide also known as Byetta, Bydureon Drug

Byetta 5 to 10 ug (twice daily) Bydureon 2mg (once weekly)
Placebo Drug

Placebo for Dapagliflozin

Main thing measured	Change in Endogenous Glucose Production (EGP) After Acute Exposure to a Single Dose and Again After 16 Weeks of Treatment
Sponsor	The University of Texas Health Science Center at San Antonio
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02981069 ↗